Enanta Pharmaceuticals (ENTA) Research & Development (2012 - 2026)
Enanta Pharmaceuticals posted quarterly Research & Development of $19.4 million for Q1 2026, down 30.72% year-on-year from $28.1 million in Q1 2025, and down 6.79% on a QoQ basis from $20.9 million in Q4 2025.
Enanta Pharmaceuticals (ENTA) has 15 years of Research & Development data on file, last reported at $19.4 million in Q1 2026.
- For the quarter ending Q1 2026, Research & Development fell 30.72% year-over-year to $19.4 million; the trailing twelve-month figure through Mar 2026 stood at $91.3 million (down 20.76% YoY), and the FY2025 full-year result was $106.7 million, down 18.81% from the prior year.
- Research & Development for Q1 2026 stood at $19.4 million, down from $20.9 million in the prior quarter.
- Across five years, Research & Development topped out at $43.5 million in Q1 2023 and bottomed at $19.4 million in Q1 2026.
- The 5-year median for Research & Development is $34.8 million (2022), against an average of $32.8 million.
- The widest annual swing landed in 2023, when Research & Development grew 9.97%; it then sank 33.14% in 2024.
- A 5-year view of Research & Development shows it stood at $40.9 million in 2022, then decreased by 11.08% to $36.4 million in 2023, then fell by 23.96% to $27.7 million in 2024, then dropped by 24.58% to $20.9 million in 2025, then declined by 6.79% to $19.4 million in 2026.
- The last three Research & Development figures came in at $19.4 million (Q1 2026), $20.9 million (Q4 2025), and $23.8 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 626,092.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 4.32 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -101.30 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 1.46 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 961.60 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -2.30 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 1.54 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 364.87 Mn |
| 10 | Enanta Pharmaceuticals | 367.22 Mn | 203.44 Mn | - | 19.44 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 19.44 Mn |
| Dec 31, 2025 | 20.86 Mn |
| Sep 30, 2025 | 23.81 Mn |
| Jun 30, 2025 | 27.21 Mn |
| Mar 31, 2025 | 28.07 Mn |
| Dec 31, 2024 | 27.66 Mn |
| Sep 30, 2024 | 30.78 Mn |
| Jun 30, 2024 | 28.74 Mn |
| Mar 31, 2024 | 35.59 Mn |
| Dec 31, 2023 | 36.37 Mn |
| Sep 30, 2023 | 36.17 Mn |
| Jun 30, 2023 | 42.99 Mn |
| Mar 31, 2023 | 43.47 Mn |
| Dec 31, 2022 | 40.90 Mn |
| Sep 30, 2022 | 34.80 Mn |
| Jun 30, 2022 | 39.09 Mn |
| Mar 31, 2022 | 42.09 Mn |
| Dec 31, 2021 | 48.55 Mn |
| Sep 30, 2021 | 48.95 Mn |
| Jun 30, 2021 | 46.99 Mn |
| Mar 31, 2021 | 41.51 Mn |
| Dec 31, 2020 | 36.67 Mn |
| Sep 30, 2020 | 36.69 Mn |
| Jun 30, 2020 | 34.68 Mn |
| Mar 31, 2020 | 32.61 Mn |
| Dec 31, 2019 | 32.78 Mn |
| Sep 30, 2019 | 38.72 Mn |
| Jun 30, 2019 | 34.46 Mn |
| Mar 31, 2019 | 34.16 Mn |
| Dec 31, 2018 | 34.88 Mn |
| Sep 30, 2018 | 26.92 Mn |
| Jun 30, 2018 | 28.49 Mn |
| Mar 31, 2018 | 21.48 Mn |
| Dec 31, 2017 | 17.96 Mn |
| Sep 30, 2017 | 16.51 Mn |
| Jun 30, 2017 | 15.41 Mn |
| Mar 31, 2017 | 13.00 Mn |
| Dec 31, 2016 | 12.53 Mn |
| Sep 30, 2016 | 11.50 Mn |
| Jun 30, 2016 | 10.79 Mn |
| Mar 31, 2016 | 9.14 Mn |
| Dec 31, 2015 | 9.03 Mn |
| Sep 30, 2015 | 7.05 Mn |
| Jun 30, 2015 | 6.25 Mn |
| Mar 31, 2015 | 5.37 Mn |
| Dec 31, 2014 | 4.52 Mn |
| Sep 30, 2014 | 5.20 Mn |
| Jun 30, 2014 | 4.55 Mn |
| Mar 31, 2014 | 4.72 Mn |
| Dec 31, 2013 | 4.26 Mn |
| Sep 30, 2013 | 4.30 Mn |
| Jun 30, 2013 | 4.04 Mn |
| Mar 31, 2013 | 3.70 Mn |
| Dec 31, 2012 | 4.80 Mn |
| Sep 30, 2012 | 4.26 Mn |
| Jun 30, 2012 | 4.93 Mn |
| Mar 31, 2012 | 3.26 Mn |